TABLE 3.
NAFLD activity scores (NAS) used to evaluate morphological changes in the experimental groups
| Parameters | Control | HFD | HFD + Ax10 | HFD + Ax30 | HFD + Ax60 | Negative | HFD + FGF(−) | HFD + FGF(−) + Ax |
|---|---|---|---|---|---|---|---|---|
| Steatosis (0–3) | 0.20 ± 0.45 | 2.14 ± 0.69# | 2.01 ± 0.48 | 1.84 ± 0.38 | 1.43 ± 0.53* | 0.29 ± 0.49 | 2.43 ± 0.53& | 1.86 ± 0.69%,+ |
| Lobular inflammation (0–3) | 0.00 ± 0.00 | 1.85 ± 0.69# | 1.69 ± 0.48 | 1.49 ± 0.48* | 1.42 ± 0.53* | 0.14 ± 0.38 | 2.28 ± 0.49& | 1.71 ± 0.49%,+ |
| Hepatocellular ballooning (0–2) | 0.00 ± 0.00 | 1.71 ± 0.49# | 1.67 ± 0.53 | 1.52 ± 0.53 | 1.14 ± 0.69* | 0.14 ± 0.38 | 1.85 ± 0.38 | 1.43 ± 0.53% |
| NAS | 0.20 ± 0.45 | 4.57 ± 0.77# | 4.34 ± 0.69 | 3.81 ± 0.63* | 3.57 ± 0.53* | 0.43 ± 0.53 | 5.14 ± 0.53& | 4.43 ± 0.79%,+ |
Data shown are means ± SD; n=7 per group. # P < .05, significantly different from control; * P < .05, significantly different from HFD; + P < .05, significantly different from HFD + Ax60; & P < .05, significantly different from Negative; % P < .05, significantly different from HFD + FGF(−).